Carbiogene Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CBG-002 / Carbiogene Therap
NCT04637269: Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

Recruiting
1
16
RoW
anti-BCMA CAR-T
Xinqiao Hospital of Chongqing, Carbiogene Therapeutics Co. Ltd.
Multiple Myeloma
11/21
11/23
NCT04706936: Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Recruiting
1
25
RoW
anti-BCMA CAR-T, CBG-002 CAR-T, Cyclophosphamid, Fludarabine
Second Affiliated Hospital, School of Medicine, Zhejiang University, Carbiogene Therapeutics Co. Ltd.
Relapsed or Refractory Multiple Myeloma
10/23
04/24
NCT06705725: Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

Not yet recruiting
1
38
NA
CBG002 CAR-T Cell Suspension
Carbiogene Therapeutics Co. Ltd.
Multiple Myeloma
10/27
02/28
CBG-006 / Carbiogene Therap
ChiCTR2100044169: Clinical study of autologous T cells modified with ILT3 chimeric antigen receptor for relapsed/refractory acute myeloid leukemia (M4/M5)

Recruiting
N/A
25
 
Anti-ILT3 CAR-T cells
Zhejiang Provincal People's Hospital; Zhejiang Provincal People's Hospital, Key R&D Program of Zhejiang Province (No. 2019C03036)/Carbiogene Therapeutics Co. Ltd.
Acute myeloid leukemia (M4/M5)
 
 
ChiCTR2100044163: Clinical study of autologous T cells modified with ILT3 chimeric antigen receptor for relapsed/refractory acute myeloid leukemia (M4/M5)

Recruiting
N/A
25
 
Anti-ILT3 CAR-T cells
Zhejiang Provincal People's Hospital; Zhejiang Provincal People's Hospital, Key R&D Program of Zhejiang Province (No. 2019C03036)/Carbiogene Therapeutics Co. Ltd.
Acute myeloid leukemia (M4/M5)
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CBG-002 / Carbiogene Therap
NCT04637269: Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

Recruiting
1
16
RoW
anti-BCMA CAR-T
Xinqiao Hospital of Chongqing, Carbiogene Therapeutics Co. Ltd.
Multiple Myeloma
11/21
11/23
NCT04706936: Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Recruiting
1
25
RoW
anti-BCMA CAR-T, CBG-002 CAR-T, Cyclophosphamid, Fludarabine
Second Affiliated Hospital, School of Medicine, Zhejiang University, Carbiogene Therapeutics Co. Ltd.
Relapsed or Refractory Multiple Myeloma
10/23
04/24
NCT06705725: Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

Not yet recruiting
1
38
NA
CBG002 CAR-T Cell Suspension
Carbiogene Therapeutics Co. Ltd.
Multiple Myeloma
10/27
02/28
CBG-006 / Carbiogene Therap
ChiCTR2100044169: Clinical study of autologous T cells modified with ILT3 chimeric antigen receptor for relapsed/refractory acute myeloid leukemia (M4/M5)

Recruiting
N/A
25
 
Anti-ILT3 CAR-T cells
Zhejiang Provincal People's Hospital; Zhejiang Provincal People's Hospital, Key R&D Program of Zhejiang Province (No. 2019C03036)/Carbiogene Therapeutics Co. Ltd.
Acute myeloid leukemia (M4/M5)
 
 
ChiCTR2100044163: Clinical study of autologous T cells modified with ILT3 chimeric antigen receptor for relapsed/refractory acute myeloid leukemia (M4/M5)

Recruiting
N/A
25
 
Anti-ILT3 CAR-T cells
Zhejiang Provincal People's Hospital; Zhejiang Provincal People's Hospital, Key R&D Program of Zhejiang Province (No. 2019C03036)/Carbiogene Therapeutics Co. Ltd.
Acute myeloid leukemia (M4/M5)
 
 

Download Options